Pharm Flashcards
Km
=[S] at 1/2 Vmax; inverse to affinity for substrate
Vmax
Directly proportional to enzyme concentration (V of saturation)
Competitive inhibitor
Same Vmax, lower Km (takes longer to reach vmax); reversible
Noncompetitive inhibitor
Higher Km, lower Vmax
Cooperative kinetics
Sigmoid curve (like hemoglobin)
Most enzymes have a ____ curve
Hyperbolic
On a lineweaver burk plot
High y intercept = lower V max (1/V on Y axis); further right x intercept (closer to zero) –> higher Km, lower affinity
Reversible competitive inhibitors -- Resemble substrate Overcome by increased [S] Bind active site Effect on Vmax Effect on Km Pharmacodynamics
Resemble substrate: yes Overcome by increased [S]: yes Bind active site: yes Effect on Vmax: no change Effect on Km: increased Pharmacodynamics: decreased potency
Irreversible competitive inhibitors -- Resemble substrate Overcome by increased [S] Bind active site Effect on Vmax Effect on Km Pharmacodynamics
Resemble substrate: yes Overcome by increased [S]: no Bind active site: yes Effect on Vmax: decreased Effect on Km: no change Pharmacodynamics: decreased efficacy
Noncompetitive inhibitors -- Resemble substrate Overcome by increased [S] Bind active site Effect on Vmax Effect on Km Pharmacodynamics
Resemble substrate: yes Overcome by increased [S]: no Bind active site: yes Effect on Vmax: decreased Effect on Km: no change Pharmacodynamics: decreased efficacy Compared to uncompetitive -- binds equally well no matter whether substrate is bound
Uncompetitive inhibitor
Only binds to an enzyme bound to substrate
Decreases Vmax, decreases Km (increased sticking in enzyme); parallel on LB plot
Vd=
Amount drug in body/plasma drug conc
Low Vd compartment and type
Intravascular large/charged molecules often bound to plasma proteins
Medium Vd compartment and type
ECF small hydrophilic molecules
High Vd compartment and type
All tissues including fat, small lipophilic molecules, esp if bound to tissue protein
CL=
rate of elimination/plasma drug conc. (volume of plasma cleared of drug per unit of time)
aka Vd*Ke (elimination const)
How many half lives to reach steady state in 1st order kinetics?
4-5
How many half lives to reach 90% of steady state in first order kinetics?
3.3
T1/2 in first order kin=
(0.693*Vd)/CL
Loading dose=
(Cp*Vd)/F
Where Cp is conc. at steady state
F is bioavailability
Maintenance dose=
(CpCLt)/F
Where Cp is conc at steady state
F is bioavailability
t is dosage interval
In renal and liver disease, how do maintenance doses change?
Maintenance goes down
In renal and liver disease, how do loading doses change?
Loading dose doesn’t change (trick q)
Additive drug effect
Effect of A+B=sum of individual effects
Permissive drug effect
Need A for proper fxn of B
Synergistic drug effect
A+B together > sum of their effects individually
Tachyphlactic drug interaction
Acute decrease in reponse to drug after initial/repeated admin
Zero order elim
Rate of elim constant regardless of Cp; eg Phenytoin, ethanol, aspirin at high conc. (constant AMOUNT)
First order elim
Rate of elim directly proportional to drug conc. (constant FRACTION), Cp decreases exponentially w/ time; e.g. most drugs
Weak acids and how to get rid of them in overdose
Ex: phenobarb, methotrexate, aspirin
Trapped in basic environments – give sodium bicarb to alk the urine
Weak bases and how to get rid of them in overdowse
Ex: amphetimines, TCAs
Trapped in acidic environments – give ammonium Cl to acidify urine
Phase I metabolism
Reduction, oxidation, hydrolysis w P50 –> slightly polar, water soluble metabolites (often still active)
First type of metabolism lost w/ age
Phase I
Phase II metabolism
Conjugation (Methylation, glucuronidation, acetylation, sulfation) –> very polar inactive metabolites that can be renally excreted
Slow acetylators have increased side effects from some drugs due to slower metabolism
Efficacy
Maximal effect a drug can produce (Vmax)
Partial agonist efficacy vs full agonist efficacy
Partial
Potency
Amount of drug needed for a given effect (EC50 – i.e. 50% of maximal effect)
Left shift in potency=
Lower EC50, higher potency, less drug needed for an effect
Competitive antagonist
Right shift in curve –i.e. lower potency, but same efficacy and can be overcome by increased substrate conc
Noncompetitive antagonist
Shifts curve down (lower efficacy) – not able to be overcome by a higher [S]
Partial agonists
Same site as a full agonist, decreases efficacy, potency independent
Therapeutic index
Measurement of drug safety
TD50/ED50 (toxic median dose/effective median dose)
Therapeutic window
Dosage range to safely/effectively treat disease
Lower TI drugs
Require monitoring; eg Warfarin, theophylline, dig, Li,
“Warning These Drugs are Lethal!”
All first synapses are
Ach on Nicotinic receptors
PNS has long/short pre synaptic
Long
SNS has long/short pre synaptic
Short
Exception to SNS rules
Sweat glands – Ach on M like PNS
alpha1
Gq
Vascular smooth muscle contraction, pupillary dilator contracts (mydriasis); intestinal/bladder sphincter contraction
alpha2
Gi
Less sympathetic outflow, less insulin release, less lipolysis, increased platelet agg, less aqueous humor made
beta1
Gs
Increased heart rate, increased contractility, renin released, increased lipolysis
beta2
Gs
Vasodilation, bronchodilation, increased lipolysis, increased insulin release, less uterine tone (tocolysis), ciliary muscle relaxation, more aqueous humor
beta3
Gs
Increased lipolysis, thermogenesis in skeletal m, bladder relaxation
M1
Gq
Higher cognitive fxns, stimulates enteric nervous system
M2
Gi
Lower heart rate, less atrial contractility
M3
Gq
Increases exocrine gland secretions (lacrimal, sweat, salivary, gastric acid), causes gut peristalsis, bladder contraction, bronchoconstriction, pupillary muscle contraction (miosis), ciliary muscle contraction (accomodation), increases release of insulin
D1
Gs
Relaxes renal vascular smooth muscle, activates direct pathway of striatum
D2
Gi
Modulates transmitter release (esp in brain), inhibition of indirect pathway of striatum
(GI, Inhibition Indirect path)
H1
Gq
Nasal and bronchial muscus production, vascular permeability, contraction of bronchioles, pruritus, pain
H2
Gs
Gastric acid secretion
V1
Gq
Vascular smooth muscle contraction
V2
Gs
H2O permeability and reabsorption in collecting tubules of kidney
Gq receptor examples and effector enzyme
H1, alpha1, V1, M1, M3
“HAVe 1 M&M”
Works via PLC (Ca/PKC)
Gs receptor examples and effector enzyme
B1, B2, B3, D1, H2, V2
Works via AC upregulation
Gi receptor examples and effector enzyme
M2, alpha2, D2
Works via AC downregulation
NE self regulation
Via alpha2 autoreceptors
Selective beta blockers (6)
B1 – acebutolol (partial agonist), atenolol, betaxolol, bisoprolol, esmolol, metoprolol
Non selective beta blockers (4)
Nadolol, pindolol (partial agonist), propanolol, timolol
Nonselective beta/alpha blockers
Labetolol, carvedilol
Special beta blockers
Nebivolol – cardiac selective B1, stim of B3 in vasculature –> NO synthase –> reduces SVR
B blockers that reduce mortality in HF
Bisoprolol, carvedilol, metoprolol
B blocker partial agonists
Pindolol, acebutalol (don’t use in heart failure)
Tetrodotoxin – source, action, symptoms, tx
Pufferfish – highly potent, binds voltage gated Na channels in heart/nerve –> prevents depolarization –> leads to nausea, diarrhea, paresthesias, weakness, dizziness, lost of reflexes (tx supportive)
Ciguatoxin – source, action, symptoms, tx
Reef fish (barracuda, snapper, moray eel) –> opens Na channels –> depolarization –> NVD, perioral numbness, reversal of hot/cold sensations, bradycardia, heart block, hypotension (tx supportive)
Histaime (scombroid poisoning) – source, action, symptoms, tx
From spoiled dark-meat fish like tuna, mahimahi, mackerel, bonito –> bacterial histidine decarboxylase causes histadine –> histamine –> mimics anaphylaxis (tx: antihistamines, albuterol and epi if needed)